Spots Global Cancer Trial Database for Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial
Official Title: Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions
Study ID: NCT03289260
Study Description
Brief Summary: AdAM is a prospective, randomized, controlled, double-blinded, monocentric trial in patients receiving surgical therapy due to anal HPV infection. Aim of the study is to evaluate efficacy of combination therapy (surgical therapy + topical Imiquimod-therapy). It is planned to include 200 patients. 100 patients receive surgical therapy+ topical Imiquimod therapy, 100 patients receive surgical therapy + topical Placebo therapy
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Visceral-, Transplant- and Thoracic Surgery, Innsbruck, Tyrol, Austria
Contact Details
Name: Dietmar Öfner-Velano, MD
Affiliation: University Hospital for Visceral, Transplant and Thoracic Surgery
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
